Deals
Merck Pays $400 Million Upfront for SciBrunch's Preclinical KRAS G12D Inhibitor in a Deal Worth Up to $2.13 Billion
The exclusive global license covers SPR2015, a molecular glue targeting one of oncology's most persistent mutations, and triggers a $0.13-per-share charge in Merck's third quarter.
AF
By Anna Ferreira
Sep 28, 2026 · 5 min read
Merck said Monday it has entered an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D inhibitor, paying $400 million upfront in a transaction with a potential aggregate value of about $2.13 billion.
Discussion (0)
Sign in to join the discussion.
Loading comments…
AF
Anna Ferreira
Senior Correspondent, Corporate Strategy
Anna Ferreira writes for Corporate Insider Inc.